Lyell Immunopharma Inc
NASDAQ:LYEL
Intrinsic Value
Lyell Immunopharma, Inc. operates as a holding company, which engages in the development of cell-based immunotherapies for human diseases. [ Read More ]
The intrinsic value of one LYEL stock under the Base Case scenario is 1.17 USD. Compared to the current market price of 2.3 USD, Lyell Immunopharma Inc is Overvalued by 49%.
Valuation Backtest
Lyell Immunopharma Inc
Run backtest to discover the historical profit from buying and selling LYEL stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Lyell Immunopharma Inc
Current Assets | 554.7m |
Cash & Short-Term Investments | 546.2m |
Other Current Assets | 8.5m |
Non-Current Assets | 195.3m |
Long-Term Investments | 48.5m |
PP&E | 142.3m |
Other Non-Current Assets | 4.5m |
Current Liabilities | 34.5m |
Accounts Payable | 4.8m |
Accrued Liabilities | 28.1m |
Other Current Liabilities | 1.6m |
Non-Current Liabilities | 60.6m |
Other Non-Current Liabilities | 60.6m |
Earnings Waterfall
Lyell Immunopharma Inc
Revenue
|
130k
USD
|
Operating Expenses
|
-247.1m
USD
|
Operating Income
|
-247m
USD
|
Other Expenses
|
12.4m
USD
|
Net Income
|
-234.6m
USD
|
Free Cash Flow Analysis
Lyell Immunopharma Inc
LYEL Profitability Score
Profitability Due Diligence
Lyell Immunopharma Inc's profitability score is 12/100. The higher the profitability score, the more profitable the company is.
Score
Lyell Immunopharma Inc's profitability score is 12/100. The higher the profitability score, the more profitable the company is.
LYEL Solvency Score
Solvency Due Diligence
Lyell Immunopharma Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
Lyell Immunopharma Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
LYEL Price Targets Summary
Lyell Immunopharma Inc
According to Wall Street analysts, the average 1-year price target for LYEL is 6.12 USD with a low forecast of 4.04 USD and a high forecast of 9.45 USD.
Ownership
LYEL Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
LYEL Price
Lyell Immunopharma Inc
Average Annual Return | -55.39% |
Standard Deviation of Annual Returns | 1.38% |
Max Drawdown | -92% |
Market Capitalization | 584.1m USD |
Shares Outstanding | 254 100 000 |
Percentage of Shares Shorted | 10.15% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Lyell Immunopharma, Inc. operates as a holding company, which engages in the development of cell-based immunotherapies for human diseases. The company is headquartered in South San Francisco, California and currently employs 219 full-time employees. The company went IPO on 2021-06-17. The firm offers T cells to cure patients with solid tumors. Its technologies are designed to be applied in a target and agnostic manner to chimeric antigen receptor (CAR), tumor-infiltrating lymphocytes (TIL) and T cell receptor (TCR) therapies to improve the properties of T cells to eradicate solid tumors. The company builds a multi-modality product pipeline across solid tumor indications with unmet needs and anticipate having investigational new drug application (IND). The company offers Gen-R and Epi-R technology platforms. Its Gen-R is its ex vivo genetic reprogramming technology to overcome T cell exhaustion. Its Epi-R is an ex vivo epigenetic reprogramming technology to create a population of T cells with durable stemness. Epi-R is designed to generate populations of T cells which have this property of durable stemness. The company utilizes its Gen-R and Epi-R technology platforms to develop a multi-modality product pipeline.
Contact
IPO
Employees
Officers
The intrinsic value of one LYEL stock under the Base Case scenario is 1.17 USD.
Compared to the current market price of 2.3 USD, Lyell Immunopharma Inc is Overvalued by 49%.